DOCSLIB.ORG

Panax Ginseng C.A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Panax Ginseng C.A 12 March 2013 EMA/HMPC/321232/2012 Committee on Herbal Medicinal Products (HMPC) Assessment report on Panax ginseng C.A. Meyer, radix Based on Article 16d(1), Article 16f and Article 16h of Directive 2001/83/EC as amended (traditional use) Draft Herbal substance(s) (binomial scientific name Whole or cut dried root, designated white ginseng; of the plant, including plant part) treated with steam and then dried, designated red ginseng, of Panax ginseng C.A.Meyer Herbal preparation(s) White ginseng: A) Comminuted herbal substance B) Powdered herbal substance C) Dry extract (DER 2-7:1), extraction solvent ethanol 34-40% V/V D) Dry extract (DERgenuine 3-7:1), extraction solvent ethanol 40% V/V, containing 4% ginsenosides (sum of Rb1, Rb2, Rc, Rd, Re, Rf, Rg1, Rg2) E) Dry extract (DER 3-7:1), extraction solvent ethanol 57.9% V/V (=50% m/m) - 60% V/V F) Dry extract (DER 3.3-5:1), extraction solvent methanol 60% V/V G) Soft extract (DER 1.7-3.2:1), extraction solvent ethanol 60-70% V/V H) Soft extract (DER 2-6:1), extraction solvent methanol 30% V/V I) Liquid extract (DER 1:0.8-1.2), extraction solvent ethanol 30.5% V/V (=25% m/m) – 34% V/V J) Liquid extract (DER 1:11-13.6), extraction solvent liquor wine Red Ginseng: K) Powdered herbal substance L) Dry extract (DER 2-4.5:1), extraction solvent ethanol 60% V/V 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7051 E-mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged. Pharmaceutical forms Comminuted herbal substance (herbal preparation A) as herbal tea for oral use. Herbal preparations B, C, E, F, K, L in solid dosage form for oral use. Herbal preparations G, H, I, J in liquid dosage form for oral use. Herbal preparation D in solid and liquid dosage form. Rapporteur Assessor(s) Note: This draft Assessment Report is published to support the release for public consultation of the draft Community herbal monograph on Panax ginseng C.A. Meyer, radix. It should be noted that this document is a working document, not yet edited, and which shall be further developed after the release for consultation of the monograph. Interested parties are welcome to submit comments to the HMPC secretariat, which the Rapporteur and the MLWP will take into consideration but no ‘overview of comments received during the public consultation’ will be prepared in relation to the comments that will be received on this assessment report. The publication of this draft assessment report has been agreed to facilitate the understanding by Interested Parties of the assessment that has been carried out so far and led to the preparation of the draft monograph. Assessment report on Panax ginseng C.A. Meyer, radix EMA/HMPC/321232/2012 Page 2/123 Table of contents Table of contents ................................................................................................................... 3 1. Introduction ....................................................................................................................... 4 1.1. Description of the herbal substance(s), herbal preparation(s) or combinations thereof .. 4 1.2. Information about products on the market in the Member States ............................... 6 1.3. Search and assessment methodology ..................................................................... 8 2. Historical data on medicinal use ........................................................................................ 8 2.1. Information on period of medicinal use in the Community ......................................... 8 2.2. Information on traditional/current indications and specified substances/preparations .. 27 2.3. Specified strength/posology/route of administration/duration of use for relevant preparations and indications ....................................................................................... 29 3. Non-Clinical Data ............................................................................................................. 31 3.1. Overview of available pharmacological data regarding the herbal substance(s), herbal preparation(s) and relevant constituents thereof ........................................................... 31 3.2. Overview of available pharmacokinetic data regarding the herbal substance(s), herbal preparation(s) and relevant constituents thereof ........................................................... 53 3.3. Overview of available toxicological data regarding the herbal substance(s)/herbal preparation(s) and constituents thereof ....................................................................... 55 3.4. Overall conclusions on non-clinical data ................................................................ 59 4. Clinical Data ..................................................................................................................... 60 4.1. Clinical Pharmacology ......................................................................................... 60 4.1.1. Overview of pharmacodynamic data regarding the herbal substance(s)/preparation(s) including data on relevant constituents ........................................................................ 60 4.1.2. Overview of pharmacokinetic data regarding the herbal substance(s)/preparation(s) including data on relevant constituents ........................................................................ 64 4.2. Clinical Efficacy .................................................................................................. 67 4.2.1. Dose response studies...................................................................................... 67 4.2.2. Clinical studies (case studies and clinical trials) ................................................... 67 4.2.3. Clinical studies in special populations (e.g. elderly and children) .......................... 112 4.3. Overall conclusions on clinical pharmacology and efficacy ...................................... 112 5. Clinical Safety/Pharmacovigilance ................................................................................. 112 5.1. Overview of toxicological/safety data from clinical trials in humans ......................... 112 5.2. Patient exposure .............................................................................................. 116 5.3. Adverse events and serious adverse events and deaths ........................................ 116 5.4. Laboratory findings ........................................................................................... 118 5.5. Safety in special populations and situations ......................................................... 118 5.6. Overall conclusions on clinical safety ................................................................... 122 6. Overall conclusions ........................................................................................................ 123 Annex ................................................................................................................................ 123 Assessment report on Panax ginseng C.A. Meyer, radix EMA/HMPC/321232/2012 Page 3/123 1. Introduction 1.1. Description of the herbal substance(s), herbal preparation(s) or combinations thereof • Herbal substance(s) Ginseng radix (European Pharmacopoeia): Ginseng radix consists of the whole or cut dried root, designated white ginseng, treated with steam and then dried, designated red ginseng, of Panax ginseng C.A. Meyer and contains not less than 0.40% for the sum of ginsenosides Rg1 and Rb1 (dried drug). Constituents (Wichtl 2009, Hänsel & Sticher 2010) Ginsenosides: 2-3%, Triterpensaponins: Dammarane and Oleanolic acid derivatives More than 200 saponins have been isolated from ginseng species, including roots (processed and native), leaves, stems, flower buds, berries, and seeds. Regarding the chemical structure, ginseng saponins are divided into several groups. The two major groups are protopanaxadiol (PPD)-type saponins with sugar moieties attached to the C3 and/or C20, and the protopanaxatriol (PPT)-group with sugar moieties at C6 and/or C20. Other types include the ocotillol-type with a five-membered epoxy- ring at C20, the oleanane –type with a nonsteroidal structure and the dammarane type with a modified C20 side chain. The nomenclature of the ginsenosides (Ra, Rb, Rc, etc.) is related to the TLC-Rf-value, whereby the polarity is decreasing from Ra to Rf, correlating to the grade of glycosylation. So far, from the roots of Panax ginseng about 50 ginsenosides have been identified, mostly belonging to the neutral, bisdesmosidic type (Rb1, Rc, Re, Rg1), but also monodesmosides are present (Rf, Rg2). In general the sugar chains are not branched. Except Rg3, Rg2, Rh1 and Rs3 all ginsenosides from the unprocessed roots are of 20(S)-PPT or 20(S)-PPD-type. 20(R)-derivatives are characteristic for red ginseng and can be seen as artifacts arising during the treatment with steam. Malonylginsenosides (e.g. mRb1, mRb2) are only present in white ginseng, the malonyl-group is cleaved during the steam processing. (Hänsel & Sticher 2010) Not only red and white ginseng, but also roots and leaves show considerable differences in the ginsenoside spectrum. Especially the small rootlets (“slender tails”) are rich in ginsenosides. Therefore, the qualitative and quantitative composition of and the ratio between certain ginsenosides in ginseng preparations allow conclusions about the
Load more

Recommended publications
  • Anticarcinogenic Effect of Panax Ginseng C.A. Meyer and Identification of Active Compounds
    J Korean Med Sci 2001; 16(Suppl): S6-18 Copyright � The Korean Academy ISSN 1011-8934 of Medical Sciences Anticarcinogenic Effect of Panax ginseng C.A. Meyer and Identification of Active Compounds The failure to improve the five-year survival rate of cancer patients, from one in Taik-Koo Yun, Yun-Sil Lee, three in the 1960s to one in two in the 1970s, stimulated awareness of the impor- You Hui Lee*, Shin Il Kim* tance of primary prevention of cancer. Korean investigators carried out extensive Hyo Yung Yun� long-term anticarcinogenicity experiments with 2000 newborn mice to investigate Laboratory of Experimental Pathology, Korea whether Panax ginseng C.A. Meyer inhibited carcinogenesis induced by several Cancer Center Hospital, Seoul; Korea Ginseng & chemical carcinogens in 1978. There was a 22% decrease (p<0.05) in the inci- Tobacco Research Institute*, Taejon; Department � dence of urethane induced lung adenoma by the combined use of red ginseng of Surgery, College of Medicine , Chungbuk National University Hospital, Cheongju, Korea extract. In the group sacrificed at 56 weeks after the treatment with aflatoxin B1, the incidence of hepatoma significantly decreased to 75% by the addition of red ginseng extract (p<0.05). The result showed that natural products can provide hope for human cancer prevention. By the newly established‘ 9 week medium- term anticarcinogenicity test model of lung tumors in mice’(Yun’s model), we confirmed significant anticarcinogenic effects of powders and extracts of the 6- yr-old dried fresh ginseng, 5- and 6-yr old white ginsengs, and 4-, 5-, and 6-yr old red ginseng.
    [Show full text]
  • Assessment Report on Panax Ginseng C.A. Meyer, Radix Based on Article 16D(1), Article 16F and Article 16H of Directive 2001/83/EC As Amended (Traditional Use)
    25 March 2014 EMA/HMPC/321232/2012 Committee on Herbal Medicinal Products (HMPC) Assessment report on Panax ginseng C.A. Meyer, radix Based on Article 16d(1), Article 16f and Article 16h of Directive 2001/83/EC as amended (traditional use) Final Herbal substance(s) (binomial scientific name Whole or cut dried root, designated white ginseng; of the plant, including plant part) treated with steam and then dried, designated red ginseng, of Panax ginseng C.A.Meyer Herbal preparation(s) White ginseng: A) Comminuted herbal substance B) Powdered herbal substance C) Dry extract (DER 2-7:1), extraction solvent ethanol 34-40% V/V D) Dry extract (DER 3-7:1), extraction solvent ethanol 40% V/V, containing 4% ginsenosides (sum of Rb1, Rb2, Rc, Rd, Re, Rf, Rg1, Rg2) E) Dry extract (DER 3-7:1), extraction solvent ethanol 57.9% V/V (=50% m/m)-60% V/V F) Dry extract (DER 3.3-5:1), extraction solvent methanol 60% V/V G) Soft extract (DER 1.7-3.2:1), extraction solvent ethanol 60%-70% V/V H) Soft extract (DER 2-6:1), extraction solvent methanol 30% V/V I) Liquid extract (DER 1: 0.8-1.2), extraction solvent ethanol 30.5% V/V (=25% m/m) – 34% V/V J) Liquid extract (DER 1:11-13.6), extraction solvent liquor wine Red ginseng: K) Powdered herbal substance L) Dry extract (DER 2-4.5:1), extraction solvent 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7051 E-mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2014.
    [Show full text]
  • Panax Notoginseng
    Journal of Applied Pharmaceutical Science Vol. 6 (08), pp. 174-178, August, 2016 Available online at http://www.japsonline.com DOI: 10.7324/JAPS.2016.60828 ISSN 2231-3354 Phytochemical and pharmacology effect of Panax notoginseng Bui Thanh Tung*, Nguyen Thanh Hai School of Medicine and Pharmacy, Vietnam National University, Office 506, Building Y1, 144 Xuan Thuy, Cau Giay, Ha Noi, Vietnam. ABSTRACT ARTICLE INFO Article history: Panax notoginseng has been shown beneficial effects on the cardiovascular system and traditionally used to Received on: 01/07/2016 prevent cerebral ischemia. It has haemostatic, antioxidant, hypolipidaemic, hepatoprotective, renoprotective and Revised on: 22/07/2016 estrogen-like activities. The phytochemical compositions of the Panax notoginseng are mainly saponins, which Accepted on: 11/08/2016 belong to protopanaxatriol and protopanaxadiol group. Furthermore, Panax notoginseng also has some Available online: 30/08/2016 compounds such as notoginsenoide, flavonoids, phytosteroid. The present review focuses on phytochemical and important pharmacology effect of Panax notoginseng including antioxidant, antiinflammation and Key words: antithrombotic activities. Panax notoginseng, antioxidant, antiinflammation, antithrombotic, phytochemical. INTRODUCTION characteristics of phytochemical and pharmacology effect of the Panax notoginseng (Burk.) F. H. Chen (Araliaceae) is a Panax notoginseng. medicinal plant. It is distributed throughout the southwest of China, Japan, Burma, Nepal and Vietnam. This plant belongs to the same family and genus as P. ginseng. The root of Panax notoginseng is normally harvested in autumn before flowering, after three years of growth. After harvesting, the roots are cleaned, divided into main root, branch root and rhizome then dried under the sun or with artificial heating at low temperatures (Wang et al., 2008).
    [Show full text]
  • Safety Assessment of Panax Spp. Root-Derived Ingredients As Used in Cosmetics
    Safety Assessment of Panax spp. Root-Derived Ingredients as Used in Cosmetics Status: Final Report for public distribution Release Date: October 5, 2012 Panel Meeting Date: September 10-11, 2012 The 2012 Cosmetic Ingredient Review Expert Panel members are: Chairman, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; Curtis D. Klaassen, Ph.D.; Daniel C. Liebler, Ph.D.; Ronald A Hill, Ph.D. James G. Marks, Jr., M.D.; Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The CIR Director is F. Alan Andersen, Ph.D. This report was prepared by Lillian C. Becker, Scientific Analyst/Writer. © Cosmetic Ingredient Review 1101 17th Street, NW, Suite 412 Washington, DC 20036-4702 ph 202.331.0651 fax 202.331.0088 [email protected] ii ABSTRACT The Cosmetic Ingredient Review Expert Panel (the Panel) reviewed the safety of 13 Panax spp. root-derived ingredients as used in cosmetics. Panax spp. is used to designate the four species being considered. Panax “spp.” indicates that multiple species within the genus are used in cosmetics, but not all species within that genus. These ingredients function mostly as skin-conditioning agents-miscellaneous, fragrance ingredients, skin conditioning agents-humectant, skin-conditioning agents- emollient, and cosmetic astringents. The Panel reviewed available animal and human data related to these ingredients. An alert to formulators about pulegone as a constituent of these ingredients and other ingredients, such as peppermint oil, was provided. The Panel concluded that these Panax spp. root-derived ingredients are safe in the practices of use and concentration as presented in this safety assessment.
    [Show full text]
  • Chemical Studies of Panax Notoginseng and Related Species, and Evaluation of Potential Antiplatelet and Anticoagulant Effects La
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by ScholarBank@NUS CHEMICAL STUDIES OF PANAX NOTOGINSENG AND RELATED SPECIES, AND EVALUATION OF POTENTIAL ANTIPLATELET AND ANTICOAGULANT EFFECTS LAU AIK JIANG NATIONAL UNIVERSITY OF SINGAPORE 2006 CHEMICAL STUDIES OF PANAX NOTOGINSENG AND RELATED SPECIES, AND EVALUATION OF POTENTIAL ANTIPLATELET AND ANTICOAGULANT EFFECTS LAU AIK JIANG (B. Sc. (Pharm.) (Hons.), NUS) A THESIS SUBMITTED FOR THE DEGREE OF DOCTOR OF PHILOSOPHY DEPARTMENT OF PHARMACY NATIONAL UNIVERSITY OF SINGAPORE 2006 ACKNOWLEDGEMENTS I would like to express my heartfelt gratitude to my thesis supervisor, Dr Koh Hwee Ling, for her patient guidance, suggestions and advice throughout the whole course of this project and thesis write-up. I would also like to extend my sincere gratitude to my co-supervisor, Dr Woo Soo On, for his helpful guidance and advice throughout this project. Under the guidance of my supervisors, I’ve learnt a lot about academic research. I am also grateful to the financial support from National University of Singapore research scholarship. The technical assistance from the laboratory officers in the Department of Pharmacy and staff from Waters Asia Ltd, is greatly appreciated too. I also wish to thank everyone in the department who have helped me in one way or another, especially my laboratory mates (namely, Huansong, Tung Kian, Yun Keng, Zou Peng and Peiling) for their help and enjoyable times in the laboratory. Special thanks also go to all my fellow friends in the department, especially Huey Ying, Yong Koy and Siok Lam, for their moral support, helpful discussions, and for sharing all the woes and wonderful times together during my postgraduate years.
    [Show full text]